Chen et al. proposed CD133/Src axis might be a potential therapeutic target in HNSCC because of being a regulatory switch to gain of EMT and of stemness properties in HNSCC [53]. The gene discussed is PROM1; the disease is head and neck squamous cell carcinoma.